Literature DB >> 17155980

Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor.

Jun Nishiguchi1, Dong Deuk Kwon, Yasuhiro Kaiho, Michael B Chancellor, Hiromi Kumon, Peter B Snyder, Naoki Yoshimura.   

Abstract

OBJECTIVE: To investigate the effects of a selective type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor, IC486051, on bladder activity in normal rats and those with and bladder outlet obstruction (BOO), as inhibition of PDE4 leads to elevation of intracellular cAMP levels and relaxation of smooth muscle.
MATERIALS AND METHODS: BOO was induced in female Sprague-Dawley rats by tying a silk ligature around the urethra. At 4 or 6 weeks after inducing BOO, conscious rats were assessed by cystometry with the urethral ligature intact. In unobstructed rats, blood pressure was also measured.
RESULTS: In unobstructed rats, IC486051 (0.1 mg/kg intravenously) produced no significant changes in cystometric variables, while at a dose of 0.5 mg/kg maximum voiding pressure was reduced by 34%. At both doses, there was a small, transient increase in blood pressure. In both 4- and 6-week BOO rats IC486051 dose-dependently decreased the number and amplitude of non-voiding bladder contractions by up to 80%, relative to pre-treatment values. At doses of 0.1 and 0.5 mg/kg IC486051 had no significant effect on voiding variables. In the 4-week BOO rats, a dose of 1.0 mg/kg decreased bladder capacity, voided volume and residual volume by 21%, 32% and 18%, respectively. In 6-week BOO rats, a dose of 1.0 mg/kg decreased maximal voiding pressure by 17% and pressure threshold for voiding by 28%. In both groups of rats with BOO, voiding efficiency was unchanged.
CONCLUSIONS: A selective PDE4 inhibitor can effectively suppress detrusor overactivity in rats with BOO, at doses that have no effect on voiding bladder contractions. Thus, selective PDE4 inhibitors should be considered for the treatment of overactive bladder in patients with BOO.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17155980     DOI: 10.1111/j.1464-410X.2006.06643.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

1.  BK channel-mediated relaxation of urinary bladder smooth muscle: a novel paradigm for phosphodiesterase type 4 regulation of bladder function.

Authors:  Wenkuan Xin; Ning Li; Qiuping Cheng; Georgi V Petkov
Journal:  J Pharmacol Exp Ther       Date:  2014-01-23       Impact factor: 4.030

Review 2.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

3.  A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury.

Authors:  Feng Bao; Jennifer C Fleming; Roozbeh Golshani; Damien D Pearse; Levent Kasabov; Arthur Brown; Lynne C Weaver
Journal:  J Neurotrauma       Date:  2011-05-05       Impact factor: 5.269

4.  Prospective pharmacologic therapies for the overactive bladder.

Authors:  Karl-Erik Andersson
Journal:  Ther Adv Urol       Date:  2009-06

5.  Inhibition of phosphodiesterases relaxes detrusor smooth muscle via activation of the large-conductance voltage- and Ca²⁺-activated K⁺ channel.

Authors:  Wenkuan Xin; Qiuping Cheng; Rupal P Soder; Georgi V Petkov
Journal:  Am J Physiol Cell Physiol       Date:  2012-02-08       Impact factor: 4.249

Review 6.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 7.  Therapeutic receptor targets for lower urinary tract dysfunction.

Authors:  Naoki Yoshimura; Yasuhiro Kaiho; Minoru Miyazato; Takakazu Yunoki; Changfeng Tai; Michael B Chancellor; Pradeep Tyagi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-21       Impact factor: 3.000

8.  Effects of mirodenafil, a phosphodiesterase-5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model: physiological and immunohistochemical aspects.

Authors:  Jung Yoon Kang; Eun Kyung Kim; Kwang Myung Kim
Journal:  Korean J Urol       Date:  2013-05-14

9.  Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission.

Authors:  Ángel Agis-Torres; Paz Recio; María Elvira López-Oliva; María Pilar Martínez; María Victoria Barahona; Sara Benedito; Salvador Bustamante; Miguel Ángel Jiménez-Cidre; Albino García-Sacristán; Dolores Prieto; Vítor S Fernandes; Medardo Hernández
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

10.  Improvement of Persistent Detrusor Overactivity through Treatment with a Phytotherapeutic Agent (WSY-1075) after Relief of Bladder Outlet Obstruction.

Authors:  Su Jin Kim; Seung Hwan Jeon; Eun Bi Kwon; Hyun Cheol Jeong; Sae Woong Choi; Woong Jin Bae; Hyuk Jin Cho; U Syn Ha; Sung Hoo Hong; Ji Youl Lee; Sung Yeoun Hwang; Sae Woong Kim
Journal:  World J Mens Health       Date:  2017-10-25       Impact factor: 5.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.